 |
77 Diseases |  |
69 Trials |
|
69 Trials |  |
4434 News |  |
| «12...34353637383940414243444546» |
- | lamivudine / Generic mfg., lopinavir/ritonavir / Generic mfg.
Trial completion: Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding (clinicaltrials.gov) - Apr 10, 2014
P3, N=1500, Completed, Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
Active, not recruiting --> Completed
- | Isentress (raltegravir) / Merck (MSD)
Trial completion: EARNEST: Europe-Africa Research Network for Evaluation of Second-line Therapy (clinicaltrials.gov) - Apr 2, 2014
P3, N=1277, Completed, Sponsor: Justine Boles
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Isentress (raltegravir) / Merck (MSD)
Trial completion, Combination therapy: Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients (clinicaltrials.gov) - Mar 30, 2014
P2, N=50, Completed, Sponsor: California Collaborative Treatment Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Enrollment closed: Study of Recovery of Intestinal CD4+ and Th17 T Cells in HIV-infected Individuals on Short-term Antiretroviral Therapy (clinicaltrials.gov) - Mar 25, 2014
P=N/A, N=10, Active, not recruiting, Sponsor: University of Roma La Sapienza
Active, not recruiting --> Completed Not yet recruiting --> Active, not recruiting
- lopinavir/ritonavir / Generic mfg.
Trial withdrawal, Immunomodulating: Lopinavir and Ritonavir in Improving Immune Response to Vaccines in Patients With Complete Remission Following A Bone Marrow Transplant for Hodgkin Lymphoma (clinicaltrials.gov) - Mar 23, 2014
P=N/A, N=0, Withdrawn, Sponsor: Mayo Clinic
Not yet recruiting --> Active, not recruiting Terminated --> Withdrawn
- lopinavir/ritonavir / Generic mfg.
Enrollment change, Immunomodulating: Lopinavir and Ritonavir in Improving Immune Response to Vaccines in Patients With Complete Remission Following A Bone Marrow Transplant for Hodgkin Lymphoma (clinicaltrials.gov) - Mar 23, 2014
P=N/A, N=0, Withdrawn, Sponsor: Mayo Clinic
Terminated --> Withdrawn N=40 --> 0
- Enrollment closed: IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults (clinicaltrials.gov) - Mar 19, 2014
P=N/A, N=200, Active, not recruiting, Sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group
N=40 --> 0 Recruiting --> Active, not recruiting
- Isentress (raltegravir) / Merck (MSD)
Enrollment change: Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir (RAL-PEP) (clinicaltrials.gov) - Mar 17, 2014
P4, N=240, Recruiting, Sponsor: Hospital Clinic of Barcelona
Recruiting --> Active, not recruiting N=189 --> 240
- Selzentry (maraviroc) / ViiV Healthcare
Enrollment change: Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1:FOVIR+EMTRICITABINA + LOPINAVIR/RITONAVIR VS TENOFOVIR+EMTRICITABINA + MARAVIROC (MARAVI-PEP) (clinicaltrials.gov) - Mar 17, 2014
P4, N=240, Recruiting, Sponsor: Hospital Clinic of Barcelona
N=189 --> 240 N=189 --> 240
- || lopinavir/ritonavir / Generic mfg.
Trial initiation date, Combination therapy: PROTEKT: Kaletra in Combination With Antiretroviral Agents (clinicaltrials.gov) - Feb 25, 2014
P=N/A, N=450, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
N=189 --> 240 Initiation date: May 2007 --> Dec 2008
- | lopinavir/ritonavir / Generic mfg.
Trial completion: Drug Interactions Between Lopinavir/Ritonavir and Oral or Patch Contraceptives in HIV Infected Women (clinicaltrials.gov) - Feb 22, 2014
P2, N=32, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Initiation date: May 2007 --> Dec 2008 Active, not recruiting --> Completed
- |||| lopinavir/ritonavir / Generic mfg.
Trial completion: "OK 2004 Study" (Only Kaletra 2004 Study): Study to Evaluate Suspending Nucleosides From Triple-Drug Therapy in HIV Subjects (clinicaltrials.gov) - Feb 22, 2014
P4, N=200, Completed, Sponsor: Arribas, Jose R., M.D.
Active, not recruiting --> Completed Recruiting --> Completed
- | lopinavir/ritonavir / Generic mfg.
Trial completion: Drug Interactions of Echinacea, Ginseng, and Ginkgo Biloba Taken With Lopinavir/Ritonavir in Healthy Volunteers (clinicaltrials.gov) - Feb 22, 2014
P4, N=47, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Recruiting --> Completed Active, not recruiting --> Completed
- | Invirase (saquinavir) / Roche
Trial completion, IO biomarker: A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy (clinicaltrials.gov) - Feb 22, 2014
P2, N=6, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Effects of Anti-HIV Therapy on Treatment for Hepatitis C in HCV/HIV Infected Adults (clinicaltrials.gov) - Feb 22, 2014
P=N/A, N=2, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed No longer recruiting --> Completed
- ||||||| lopinavir/ritonavir / Generic mfg., fosamprenavir / Generic mfg.
Trial completion: KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks (clinicaltrials.gov) - Feb 22, 2014
P3, N=866, Completed, Sponsor: GlaxoSmithKline
No longer recruiting --> Completed No longer recruiting --> Completed
- | Trial completion, Combination therapy: Cyclosporine A in Combination With Abacavir Sulfate, Lamivudine, and Zidovudine and Lopinavir/Ritonavir in HIV (clinicaltrials.gov) - Feb 22, 2014
P2, N=16, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
No longer recruiting --> Completed Active, not recruiting --> Completed
- | lamivudine/zidovudine/efavirenz / Viatris, Strides Pharma Science, NN1213 / Novo Nordisk
Trial completion: Strategies for Delivering Anti-HIV Therapy in South Africa (clinicaltrials.gov) - Feb 22, 2014
P=N/A, N=813, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Recruiting --> Completed
- | lopinavir/ritonavir / Generic mfg.
Trial completion: The Effect of Lopinavir/Ritonavir on Endothelial Function (clinicaltrials.gov) - Feb 22, 2014
P1, N=30, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Recruiting --> Completed No longer recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion, IO biomarker: Anti-HIV Drug Regimens With or Without Protease Inhibitors and Drug Level Monitoring in HIV Infected Adolescents (clinicaltrials.gov) - Feb 22, 2014
P3, N=240, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
No longer recruiting --> Completed Active, not recruiting --> Completed
- |||| efavirenz / Generic mfg., lopinavir/ritonavir / Generic mfg.
Trial completion: A Simplified Kaletra (clinicaltrials.gov) - Feb 22, 2014
P2, N=150, Completed, Sponsor: Abbott
Active, not recruiting --> Completed No longer recruiting --> Completed
- | efavirenz / Generic mfg., lopinavir/ritonavir / Generic mfg.
Trial completion: Comparing the Safety, Effectiveness, and Tolerability of Three Anti-HIV Drug Regimens for Treatment-Naive Patients (clinicaltrials.gov) - Feb 22, 2014
P3, N=775, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
No longer recruiting --> Completed Active, not recruiting --> Completed
- | Invirase (saquinavir) / Roche
Trial completion, Combination therapy: Lopinavir/Ritonavir in Combination With Saquinavir Mesylate or Lamivudine/Zidovudine to Explore Metabolic Toxicities in Antiretroviral HIV-Infected Subjects (clinicaltrials.gov) - Feb 22, 2014
P2, N=30, Completed, Sponsor: Abbott
Active, not recruiting --> Completed No longer recruiting --> Completed
- | lopinavir/ritonavir / Generic mfg.
Trial completion: Safety and Effectiveness of Lopinavir/Ritonavir in HIV Infected Infants (clinicaltrials.gov) - Feb 22, 2014
P1/2, N=31, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
No longer recruiting --> Completed Active, not recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: A Study to Compare Anti-HIV Drugs Given Twice a Day or Once a Day, With or Without Direct Observation (clinicaltrials.gov) - Feb 22, 2014
P2, N=402, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Trial completion, Combination therapy: Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV (clinicaltrials.gov) - Feb 22, 2014
P3, N=571, Completed, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | tenofovir disoproxil fumarate / Generic mfg., lopinavir/ritonavir / Generic mfg., fosamprenavir / Generic mfg.
Trial completion, Combination therapy: Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People (clinicaltrials.gov) - Feb 22, 2014
P=N/A, N=56, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed No longer recruiting --> Completed
- Trial completion, Combination therapy: Atazanavir Versus Lopinavir/Ritonavir (LPV/RTV) in Patients Who Have Not Had Success With Protease Inhibitor-Containing HAART Regimen(s) (clinicaltrials.gov) - Feb 22, 2014
P3, N=0, Completed, Sponsor: Bristol-Myers Squibb
No longer recruiting --> Completed No longer recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Using Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients With Drug-resistant HIV (clinicaltrials.gov) - Feb 22, 2014
P2, N=53, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
No longer recruiting --> Completed Active, not recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: A Study of HIV-Disease Development in Aging (clinicaltrials.gov) - Feb 19, 2014
P2, N=90, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| lopinavir/ritonavir / Generic mfg.
Trial completion, Combination therapy: ABT-378/Ritonavir in Combination With Reverse Transcriptase Inhibitors in Antiretroviral Na (clinicaltrials.gov) - Feb 19, 2014
P1/2, N=100, Completed, Sponsor: Abbott
Active, not recruiting --> Completed No longer recruiting --> Completed
- lopinavir/ritonavir / Generic mfg.
Enrollment closed: ALternative TEnofovir Dosing in Adults With Moderate Renal Function Impairment (clinicaltrials.gov) - Feb 16, 2014
P1, N=40, Active, not recruiting, Sponsor: Institut de Recherche pour le Developpement
No longer recruiting --> Completed Recruiting --> Active, not recruiting
- | lopinavir/ritonavir / Generic mfg.
Trial completion: A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines (clinicaltrials.gov) - Feb 16, 2014
P2/3, N=97, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- darunavir/ritonavir / Generic mfg., lopinavir/ritonavir / Generic mfg.
Enrollment change, Monotherapy: Clinical Study to Evaluate the Efficacy and Safety of Lopinavir/Ritonavir Monotherapy Versus Darunavir/Ritonavir Monotherapies as Simplification Switching Strategies of PI/NNRTI-Triple Therapy Based-Regimens (clinicaltrials.gov) - Feb 11, 2014
P4, N=73, Completed, Sponsor: Germans Trias i Pujol Hospital
Active, not recruiting --> Completed N=102 --> 73
- darunavir/ritonavir / Generic mfg., lopinavir/ritonavir / Generic mfg.
Trial completion, Monotherapy: Clinical Study to Evaluate the Efficacy and Safety of Lopinavir/Ritonavir Monotherapy Versus Darunavir/Ritonavir Monotherapies as Simplification Switching Strategies of PI/NNRTI-Triple Therapy Based-Regimens (clinicaltrials.gov) - Feb 11, 2014
P4, N=73, Completed, Sponsor: Germans Trias i Pujol Hospital
N=102 --> 73 Active, not recruiting --> Completed
- lopinavir/ritonavir / Generic mfg.
Trial completion: Routine Use of Antiretroviral Therapy to Prevent Mother-to-Child HIV Transmission in the Kafue District of Zambia (clinicaltrials.gov) - Feb 4, 2014
P4, N=284, Completed, Sponsor: University of North Carolina, Chapel Hill
Active, not recruiting --> Completed Terminated --> Completed
- | Isentress (raltegravir) / Merck (MSD)
Enrollment closed, Combination therapy: Study of Options for Second-Line Effective Combination Therapy (SELECT) (clinicaltrials.gov) - Jan 27, 2014
P3, N=600, Active, not recruiting, Sponsor: AIDS Clinical Trials Group
Terminated --> Completed Recruiting --> Active, not recruiting
- || lopinavir/ritonavir / Generic mfg.
Enrollment change: Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection (clinicaltrials.gov) - Jan 15, 2014
P=N/A, N=236, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Active, not recruiting N=600 --> 236
- ||| lopinavir/ritonavir / Generic mfg.
Trial completion: Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection (clinicaltrials.gov) - Jan 15, 2014
P=N/A, N=236, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
N=600 --> 236 Active, not recruiting --> Completed
- || lopinavir/ritonavir / Generic mfg.
Enrollment change, Adherence: Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) Program (clinicaltrials.gov) - Jan 6, 2014
P=N/A, N=240, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed N=160 --> 240
- efavirenz / Generic mfg., nevirapine / Generic mfg., lopinavir/ritonavir / Generic mfg.
Enrollment closed, Adherence: PI or NNRTI as First-line Treatment of HIV in West Africa - the PIONA Trial (clinicaltrials.gov) - Dec 29, 2013
P4, N=400, Active, not recruiting, Sponsor: University of Aarhus
N=160 --> 240 Recruiting --> Active, not recruiting
- Isentress (raltegravir) / Merck (MSD)
Trial completion: Raltegravir + Lopinavir/Ritonavir or Emtricitabine/Tenofovir for HIV Treatment Naive Subjects (clinicaltrials.gov) - Dec 29, 2013
P2, N=44, Completed, Sponsor: Margaret A. Fischl, M.D.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Selzentry (maraviroc) / ViiV Healthcare
Enrollment closed: MARCH Central Nervous System Substudy (clinicaltrials.gov) - Dec 16, 2013
P=N/A, N=50, Active, not recruiting, Sponsor: Kirby Institute
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Enrollment open: Comparing PI-Based to a nNRTI-based ART for Clearance of Plasmodium Falciparum Parasitemia in HIV-Infected (clinicaltrials.gov) - Dec 4, 2013
P1/2, N=52, Recruiting, Sponsor: AIDS Clinical Trials Group
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- lopinavir/ritonavir / Generic mfg.
Enrollment closed: Molecular Diversity of HIV-1 Group O Strains and Treatment Management in Cameroon (clinicaltrials.gov) - Dec 2, 2013
P=N/A, N=171, Active, not recruiting, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Viracept (nelfinavir) / ViiV Healthcare, Roche
Trial completion: When to Start Anti-HIV Drugs in Children Infected With HIV (The PREDICT Study) (clinicaltrials.gov) - Dec 1, 2013
P3, N=300, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Isentress (raltegravir) / Merck (MSD)
Trial completion: Bone and Body Comp: A Sub Study of the SECOND-LINE Study (clinicaltrials.gov) - Nov 30, 2013
P4, N=211, Completed, Sponsor: Kirby Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Isentress (raltegravir) / Merck (MSD)
Trial completion: A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen (clinicaltrials.gov) - Nov 30, 2013
P4, N=558, Completed, Sponsor: Kirby Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed
- stavudine / Generic mfg., lamivudine / Generic mfg., lopinavir/ritonavir / Generic mfg.
Trial completion: Anti-HIV Treatment Interruptions in HIV Infected Adults in South Africa (clinicaltrials.gov) - Nov 18, 2013
P=N/A, N=30, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| darunavir/ritonavir / Generic mfg.
Trial completion: Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r) (clinicaltrials.gov) - Nov 17, 2013
P3, N=316, Completed, Sponsor: Janssen-Cilag G.m.b.H
Active, not recruiting --> Completed Recruiting --> Completed